Clinical Trial Update: A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma [Phase 3]

View source ↗

Summary

Clinical trial update on a Phase 3 neoadjuvant study of BCD-217 (Nurulimab + Prolgolimab) in patients with resectable Stage III skin melanoma; the trial is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Melanoma

Drugs mentioned

• BCD-217 (Nurulimab + Proglolimab)
• Nurulimab (nurulimab)
• Prolgolimab (prolgolimab)

Snippet

Sponsor: Biocad | Conditions: Melanoma Stage III, Melanoma (Skin) | Phase 3 | Status: ACTIVE_NOT_RECRUITING